Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp (NYSE American: ZOM) delivers innovative veterinary health solutions through advanced diagnostics and therapeutic technologies for companion animals and equines. This dedicated news hub provides investors and veterinary professionals with timely updates on corporate developments directly impacting animal healthcare innovation.
Access official press releases covering product launches, financial results, and strategic partnerships that shape Zomedica's position in veterinary medicine. Our curated collection ensures transparent access to regulatory filings, technology advancements, and market expansion initiatives without promotional bias.
Key updates on Zomedica's diagnostic platforms including TRUFORMA® assays, therapeutic device innovations, and clinical validation studies. Monitor operational milestones affecting veterinary practice efficiencies and animal health outcomes through verified corporate communications.
Bookmark this page for streamlined access to Zomedica's latest developments. Combine regular visits with professional financial advice when making investment or practice management decisions related to veterinary healthcare technologies.
Zomedica Corp. (NYSE American:ZOM) will be presenting at the EF Hutton Annual Global Conference on May 15, 2024. The Chief Executive Officer, Larry Heaton, will be presenting and holding investor meetings. Zomedica is a veterinary health company providing diagnostics and products for animals.
Zomedica Corp. received CE certification for its VetGuardian(R) remote contactless monitoring system, opening doors for European expansion in the $4 billion vet services market. The system utilizes radar technology for stress-free and efficient patient monitoring, enhancing operational workflow and outcomes. This milestone allows Zomedica to tap into the growing demand from veterinarians worldwide, driving innovation in the veterinary health sector.
Zomedica Corp. strengthens its market position with the issuance of three new patents for its TRUFORMA diagnostic platform. The patents cover innovative design and functionality improvements, enhancing the system's ability to detect a wide array of health conditions in horses and companion animals. With a total of 65 U.S. patents, 123 international patents, and 33 U.S. and 98 foreign trademarks, Zomedica solidifies its intellectual property portfolio and market presence in the veterinary health industry.
Zomedica Corp will report its first quarter 2024 financial results on May 9th, 2024, providing insights into its operational and financial performance. The company, focused on veterinary health products, will host a conference call and webcast to discuss the highlights of the quarter.
FAQ
What is the current stock price of Zomedica (ZOM)?
What is the market cap of Zomedica (ZOM)?
